MAPT and supranuclear palsy, progressive, 1: With the advent and improvement of tau‐specific ligands, tau positron emission tomography (PET) is emerging as a potential biomarker in the diagnosis of PSP (Schröter et al., 2020; Tagai et al., 2021).